Business
BriaCell is a clinical-stage biotechnology company developing targeted immunotherapies for cancer, led by Bria-IMT in metastatic breast cancer.
BriaCell stayed pre-revenue, widened losses and cash burn, but equity turned positive.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage breast cancer immunotherapyNote
- Revenue — No revenue in bundle financialsNote
- Losses — Net loss widened to $26.3MWatch
- Cash — Free cash flow fell to -$28.6MWatch
- Equity — Equity improved to $17.3MOK
- Insiders — 0 purchases / 0 salesNote
- Accounting — No current forensic screen in bundleNote
Leadership changes
From BriaCell Therapeutics Corp.'s own filings, the day they're filed.
- Marc Lustig · directors · departureeff. 2024-11-23
Latest filings
- 8-K · Company announcement2026-06-26
- 10-Q · Quarterly report2026-06-09
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-03-31
- 10-Q · Quarterly report2026-03-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about BriaCell Therapeutics Corp., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.